ArticleFuture science OA2021
Neutrophil percentage-to-albumin ratio predicts mortality in bladder cancer patients treated with neoadjuvant chemotherapy followed by radical cystectomy.
Open access · goldAbstract read
In one paragraph
Article in Future science OA, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed, 1 pooled it
9.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 1 synthesis or guideline pooled it, 72 citations in OpenAlex.
- The prognostic value of fibrinogen to albumin ratio in malignant tumor patients: A meta-analysis.Frontiers in oncology · 2022Pooled it
- Preoperative Platelet-to-Lymphocyte Ratio as a Predictor of Recurrence and Recurrence-Free Survival in Non-Muscle-Invasive Bladder Cancer Across Different Intravesical Therapies.Journal of clinical medicine · 2026Article
- Prognostic Value of Neutrophil Percentage-Albumin Ratio in Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors.Current oncology (Toronto, Ont.) · 2026Article
- Association Between Neutrophil Percentage-to-Albumin Ratio (NPAR) and the Prognosis of Non-Small-Cell Lung Cancer.Cancers · 2026Article
- Neutrophil Percentage-to-Albumin Ratio as a Prognostic and Predictive Biomarker in Non-Metastatic Breast Cancer Treated with Neoadjuvant Chemotherapy: Findings from a Retrospective Cohort.Diagnostics (Basel, Switzerland) · 2026Article
- Impact of sex on the association between neutrophil percentage-to-albumin ratio and mortality in perioperative patients with chronic kidney disease: a retrospective analysis of the INSPIRE database.Perioperative medicine (London, England) · 2026Article
- Association between the neutrophil-to-albumin ratio and mortality in patients undergoing tracheal intubation: a retrospective cohort study.Frontiers in medicine · 2026Article
- Association Between Neutrophil Percentage to Albumin Ratio and Disease Activity in Hospitalized Patients with Rheumatoid Arthritis: A Cross-Sectional Study.Journal of inflammation research · 2026Article
- Development and Validation of a Neutrophil Percentage-to-Albumin Ratio-Based Nomogram for Predicting Overall Survival in Locally Advanced Nasopharyngeal Carcinoma.Journal of inflammation research · 2026Article
- Neutrophil Percentage-to-Albumin Ratio: Unveiling a New Perspective on Mortality Risk in Intensive Care Unit Asthma Patients-A Retrospective Cohort Study.Mediators of inflammation · 2026Article
- Impact of Preoperative Neutrophil Percentage-to-Albumin Ratio (NPAR) on Short-Term Complications and Long-Term Prognosis in Patients Undergoing Robot-Assisted Laparoscopic Radical Surgery for Colorectal Cancer.Journal of inflammation research · 2026Article
- Association of NPAR with 90-day mortality in predominantly acute-on-chronic liver failure.Frontiers in medicine · 2026Article
- Association between preoperative neutrophil percentage-to-albumin ratio and survival outcomes in patients with colorectal cancer undergoing radical surgery: a retrospective study with external validation.Frontiers in oncology · 2026Article
- Association between albumin-related inflammatory biomarkers and breast cancer risk: A secondary analysis of NHANES 1998-2018.Medicine · 2025Observational
- The prognostic value of preoperative Neutrophil-to-Albumin ratio (NPAR) for postoperative complications and survival in colorectal cancer patients undergoing robot-assisted surgery: a retrospective cohort study.Journal of robotic surgery · 2025Article
- Neutrophil percentage-to-albumin ratio as a predictor of In-hospital mortality in infective endocarditis.Biomarkers in medicine · 2025Article
- Association between Neutrophil Percentage-to-Albumin ratio and anemia risk: a population-based study.Scientific reports · 2025Article
- Association of neutrophil-percentage-to-albumin ratio with all-cause and cardiovascular mortality in patients with diabetes and prediabetes from the NHANES 1999-2018.Scientific reports · 2025Article
- Neutrophil percentage-to-albumin ratio and the risk of all-cause and cardiovascular mortality: a 20-year follow-up cohort study of 36,428 US adults.BMC public health · 2025Article
- Neutrophil percentage to albumin ratio predicts cardiovascular and all-cause mortality in diabetes and pre diabetes patients.Scientific reports · 2025Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
43 authors at 20 institutions in 4 countries.
Matteo FerroDepartment of Urology, European Institute of Oncology, IRCSS, Milan, Italy.ORCID https://orcid.org/0000-0002-9250-7858
Dragoş-Florin BabăDepartment of Cell & Molecular Biology, University of Medicine and Pharmacy, Targu Mures, Romania.
Ottavio de CobelliDepartment of Urology, European Institute of Oncology, IRCSS, Milan, Italy.
Gennaro MusiDepartment of Urology, European Institute of Oncology, IRCSS, Milan, Italy.
Giuseppe LucarelliDepartment of Emergency & Organ Transplantation-Urology, Andrology & Kidney Transplantation Unit, University of Bari, Bari, Italy.
Daniela TerraccianoDepartment of Translational Medical Sciences, University of Naples Federico II, Naples, Italy.
Angelo PorrecaDepartment of Oncological Urology, Veneto Institute of Oncology IOV, IRCSS, Padua, Italy.
Gian Maria BusettoDepartment of Urology, 'Sapienza' University of Rome, Policlinico Umberto I Hospital, Rome, Italy.
Francesco Del GiudiceDepartment of Urology, 'Sapienza' University of Rome, Policlinico Umberto I Hospital, Rome, Italy.
Francesco SoriaDivision of Urology, Department of Surgical Sciences, AOU Citta´ della Salute e della Scienza, Turin School of Medicine, Turin, Italy.
Paolo GonteroDivision of Urology, Department of Surgical Sciences, AOU Citta´ della Salute e della Scienza, Turin School of Medicine, Turin, Italy.
Francesco CantielloDepartment of Urology, University of Catanzaro, Università 'Magna Græcia', Catanzaro, Italy.
Rocco DamianoDepartment of Urology, University of Catanzaro, Università 'Magna Græcia', Catanzaro, Italy.
Papalia RoccoDepartment of Urology, Policlinic University Campus of Bio-Medicine of Rome, Rome, Italy.
Roberto Mario ScarpaDepartment of Urology, Policlinic University Campus of Bio-Medicine of Rome, Rome, Italy.
Abdal Rahman Abu FarhanDepartment of Urology, University of Catanzaro, Università 'Magna Græcia', Catanzaro, Italy.
Riccardo AutorinoDivision of Urology, Virginia Commonwealth University Health System, Richmond, VA 23298, USA.
Antonio BresciaDepartment of Urology, European Institute of Oncology, IRCSS, Milan, Italy.
Michele MarchioniDepartment of Medical, Oral & Biotechnological Sciences, Gabriele d'Annunzio University of Chieti & Pescara, Chieti, Italy.
Andrea MariDepartment of Experimental and Clinical Medicine, Unit of Oncologic Minimally-Invasive Urology and Andrology, University of Florence, Careggi University Hospital, Florence, Italy.
Andrea MinerviniDepartment of Experimental and Clinical Medicine, Unit of Oncologic Minimally-Invasive Urology and Andrology, University of Florence, Careggi University Hospital, Florence, Italy.
Nicola LongoDepartment of Neurosciences, Human Reproduction & Odontostomatology, University of Naples Federico II, Naples, Italy.
Francesco ChianconeUrology Unit, AORN Cardarelli, Naples, Italy.ORCID https://orcid.org/0000-0001-8648-3557
Sisto Perdona'Division of Urology, National Cancer Institute IRCCS Pascale Foundation, Naples, Italy.
Biagio BaroneDepartment of Neurosciences, Human Reproduction & Odontostomatology, University of Naples Federico II, Naples, Italy.
Pietro De PlacidoDepartment of Clinical Medicine & Surgery, University of Naples Federico II, Naples, Italy.
Michele CatellaniDepartment of Urology, European Institute of Oncology, IRCSS, Milan, Italy.
Danilo BotteroDepartment of Urology, European Institute of Oncology, IRCSS, Milan, Italy.
Pasquale DitonnoDepartment of Emergency & Organ Transplantation-Urology, Andrology & Kidney Transplantation Unit, University of Bari, Bari, Italy.
Michele BattagliaDepartment of Emergency & Organ Transplantation-Urology, Andrology & Kidney Transplantation Unit, University of Bari, Bari, Italy.
Stefania ZamboniDepartment of Urology, ASST Spedali Civili di Brescia, Brescia, Italy.
Alessandro AntonelliDepartment of Urology, ASST Spedali Civili di Brescia, Brescia, Italy.
Francesco GrecoClinic of Urology, Centro Salute Uomo, Bergamo, Italy.
Giorgio Ivan RussoDepartment of Urology, University of Catania, Catania, Italy.
Salvatore SmelzoDepartment of Urology, San Raffaele Turro Hospital, San Raffaele University, Milan, Italy.
Rodolfo HurleDepartment of Urology, IRCCS Humanitas Research Hospital, Rozzano, Italy.
Nicolae CrisanDepartment of Urology, University of Medicine & Pharmacy Iuliu Haţieganu, Cluj-Napoca, Romania.
Matteo ManfrediUrology Unit - Department of Oncology, School of Medicine, University of Turin, Turin, Italy.
Francesco PorpigliaUrology Unit - Department of Oncology, School of Medicine, University of Turin, Turin, Italy.
Felice CrocettoDepartment of Neurosciences, Human Reproduction & Odontostomatology, University of Naples Federico II, Naples, Italy.
Carlo BuonerbaDepartment of Oncology & Hematology, Regional Reference Center for Rare Tumors, University of Naples Federico II, Naples, Italy.
Alina DanilescoDepartment of Cell & Molecular Biology, University of Medicine and Pharmacy, Targu Mures, Romania.
Mihai Dorin VartolomeiDepartment of Urology, European Institute of Oncology, IRCSS, Milan, Italy.
University of Naples Federico II · ITEuropean Institute of Oncology · ITMagna Graecia University · ITUniversitatea de Medicină, Farmacie, Științe și Tehnologie „George Emil Palade” din Târgu Mureș · ROUniversity of Bari Aldo Moro · ITPoliclinico Umberto I · ITUniversità Campus Bio-Medico · ITUniversity of Florence · ITUniversity of Milan · ITUniversity of Turin · ITAzienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia · ITFederico II University Hospital · ITIRCCS Humanitas Research Hospital · ITIstituto Nazionale Tumori IRCCS "Fondazione G. Pascale" · ITIstituto Oncologico Veneto · ITIuliu Hațieganu University of Medicine and Pharmacy · ROOspedale Antonio Cardarelli · ITSan Raffaele University of Rome · ITUniversity of Catania · ITUniversity of Chieti-Pescara · IT
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo investigate the prognostic role of neutrophil percentage-to-albumin ratio (NPAR) in muscle-invasive bladder cancer (MIBC) patients treated with neoadjuvant chemotherapy (NAC) and radical cystectomy (RC). PATIENTS &
methods213 patients were included. INCLUSION CRITERIA: Nonmetastatic, MIBC (cT2-T4aN0M0), at least three cycles of NAC, undergone RC and with blood count within 30 days before NAC.
resultsFive-years overall survival (OS) with NPAR >18 was 34.06% (95% CI: 18.3-50.5) and 65.37% (95% CI: 52.4-75.6) with NPAR <18. Five years cancer-specific survival (CSS) with NPAR >18 was 42.9% (95% CI: 23.9-60.7) and 74.5% (95% CI: 62.6-83.1) with NPAR <18 (p < 0.001). In multivariable analysis, NPAR increased OS of 1.3 points and CSS of 4.37 points.
conclusionHigh NPAR prior to NAC seems to be a strong predictor of OS and CSS in MIBC patients treated with NAC and RC.
Indexed as
bladder cancerneoadjuvant chemotherapyneutrophil percentage-to-albumin rationeutrophil-to-lymphocyte ratiosurvival
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.